CareDx Q3: Revenue $79.4M (+5%), net loss widens to $16.9M; adj EBITDA loss $2.5M

CareDx, Inc.

2022-Q3 EPS reported -$1.09 revenue$239,409,000

Revenue $79.4M (+5% YoY); testing services $64.8M, product $7.2M, patient/digital $7.4M.
Net loss $16.9M ($0.32 per share) vs $11.9M loss ($0.23) in Q3 2021.
Non-GAAP net loss $3.4M vs non-GAAP income $4.0M; non-GAAP EPS -$0.06 vs +$0.07.
Adjusted EBITDA loss $2.5M vs gain $4.7M; company targets positive adjusted EBITDA by H1 2023.
Delivered 46,500 patient test results (+15% YoY); cash $291.3M, no debt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CareDx, Inc. reported the third quarter ended September 30, 2022 results: revenue $79.4 million, net income net loss was $16.9 million, EPS $0.32.

Period: the third quarter ended September 30, 2022
Revenue: $79.4 million
Net income: net loss was $16.9 million
EPS: $0.32
Result: reported results

Exact text from the filing

with positive adjusted EBITDA by first half of 2023 • Delivered 46,500 patient test results, representing growth of 15% compared to third quarter of 2021 • Achieved revenue of $79.4 million, increasing 5% year-over-year • Sustained strong testing services GAAP gross margin of 73% and non-GAAP gross margin of 74% • Strong balance sheet with $291 million cash, cash

View on SEC.gov

Browse all earnings releases →

CareDx, Inc. filing history →

Source: SEC EDGAR

accession 0001217234-22-000185

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.